Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | PHGDH | O43175 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7741300 | 1.00 | MGLL (0.40) | MGLLPHGDHALDH1A1TP53CYP3A4 | |
| SCHEMBL11444353 | 0.81 | MGLL (0.39) | MGLLPHGDHALDH1A1TP53CYP3A4 | |
| SCHEMBL3074321 | 0.80 | MGLL (0.42) | MGLLPHGDHALDH1A1TP53CYP3A4 | |
| SCHEMBL27685214 | 0.78 | — | — | |
| SCHEMBL2583853 | 0.77 | MGLL (0.38) | MGLLPHGDHALDH1A1TP53CYP3A4 | |
| SCHEMBL27565787 | 0.76 | MGLL (0.39) | MGLLPHGDHALDH1A1TP53CYP3A4 | |
| SCHEMBL7742834 | 0.75 | MGLL (0.34) | MGLLPHGDHALDH1A1TP53CYP3A4 | |
| SCHEMBL7742837 | 0.75 | MGLL (0.34) | MGLLPHGDHALDH1A1TP53CYP3A4 | |
| SCHEMBL11040637 | 0.74 | CA1 (0.38) | MGLLPHGDHALDH1A1TP53CYP3A4 | |
| Ammonia Solution, Strong SCHEMBL20601168 | 0.74 | MGLL (0.37) | MGLLPHGDHALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109020-A1 | Nucleic Acid and Other Compositions and Methods for the Modulation of Cell Membranes | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-04-06 | — | — | US | disclosed |
| US-20190127682-A1 | Nucleic Acid and Other Compositions and Methods for the Modulation of Cell Membranes | NATIONAL SCIENCE FOUNDATION | 2019-05-02 | — | — | US | disclosed |
| US-8435966-B2 | Associations of xanthogenates and cyclodextrins, and their use | BIOSPHINGS AG (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20120328602-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH CERAMIDE BIOSYNTHESIS | SAINT LOUIS UNIVERSITY (US) | 2012-12-27 | — | — | US | disclosed |
| US-20100240606-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BIOSPHINGS AG (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20100086543-A1 | COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH CERAMIDE BIOSYNTHESIS | SAINT LOUIS UNIVERSITY (US) | 2010-04-08 | — | — | US | disclosed |
| CN-101522612-A | Associations of xanthogenates and cyclodextrins, and their use | BIOSPHINGS AG (DE) | 2009-09-02 | — | — | CN | disclosed |
| EP-2001840-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BioSphings AG (DE) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008122037-A2 | INHIBITORS OF THE CERAMIDE METABOLIC PATHWAY AS ADJUNCTS TO OPIATES | SAINT LOUIS UNIVERSITY (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2007112828-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | BIOSPHINGS AG (DE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109020-A1 | Nucleic Acid and Other Compositions and Methods for the Modulation of Cell Membranes | ABHD16A, PHOSPHO1, CLPTM1L | MGLL 990/4885PHGDH 2286/4885ALDH1A1 4722/4885 |
| US-20100240606-A1 | ASSOCIATIONS OF XANTHOGENATES AND CYCLODEXTRINS, AND THEIR USE | HLA-DRB1, CXCR3, ANTXR2 | MGLL 2863/4885PHGDH 4095/4885ALDH1A1 4475/4885 |
| US-20190127682-A1 | Nucleic Acid and Other Compositions and Methods for the Modulation of Cell Membranes | ABHD16A, PHOSPHO1, CLPTM1L | MGLL 990/4885PHGDH 2286/4885ALDH1A1 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.